XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas. Show more

5217 Winnebago Lane, 8201 E Riverside Dr Ste 100, Austin, TX, 78744, United States

https://www.xbiotech.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

72.87M

52 Wk Range

$2.09 - $3.61

Previous Close

$2.39

Open

$2.39

Volume

14,232

Day Range

$2.38 - $2.39

Enterprise Value

-89.56M

Cash

115.5M

Avg Qtr Burn

-8.969M

Insider Ownership

24.33%

Institutional Own.

6.74%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Natrunix + Methotrexate (MTX) Details Rheumatoid arthritis, Autoimmune disease	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Hutrukin Details Brain disease, Ischemic stroke	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Natrunix w/ ON+5FU+LV Details Cancer, Pancreatic cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Natrunix + trifluridine/tipiracil Details Cancer, Colorectal cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bermekimab Details Skin disease/disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
514G3 Details Bacterial infection, Methicillin-resistant staphylococcus aureus	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bermekimab Details Skin disease/disorder, Hidradenitis suppurativa	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.